Granules India recalls over 2.3 cr ranitidine tablets from US market
New Delhi: Drug firm Granules India is recalling over 2.3 crore ranitidine tablets, used to treat ulcers of the stomach and intestines, from the US market, the latest report of the American health regulator said.
According to the Enforcement Report of the United States Food and Drug Administration (USFDA), the company is recalling 23,090,000 Ranitidine tablets USP 150mg, 10,000 count bag on account of "CGMP deviations: Impurity N-nitrosodimethylamine (NDMA) found in API".
CGMP refers to the Current Good Manufacturing Practice regulations.
The voluntary ongoing recall is a class II recall, it added.
As per the USFDA, a class II recall is initiated in a "situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."
The tablets were distributed in Oregon, New York and New Jersey, the report said.
NDMA is classified as a probable human carcinogen (a substance that could cause cancer). It is a known environmental contaminant typically found in water and foods, including meats, dairy products and vegetables.
Read also: National Deworming Day: Haryana Health Dept to administer Albendazole tablets to 94 lakh children
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at firstname.lastname@example.org Contact no. 011-43720751 To know about our editorial team click here